REDUCE-IT
This study evaluates the effect of AMR101 on cardiovascular health and mortality in hypertriglyceridemic patients with CAD or a high risk for CAD.
PHASE: Follow Up (not taking new patients)
Principal Investigator:
Brendan Cavanaugh, MD, FACC
Sub-Investigators:
Karen Sopko, MD, FACC
Geoffrey Kunz, MD, FACC